The title compound, bis[μ-3-ethyl-5-(pyridin-2-yl)-1H-1,2,4-triazol-1-ido]bis[acetato(dimethylformamide)copper(II)], [Cu2(C9H9N4)2(C2H3O2)2(C3H7NO)2] or [Cu2(L
Et)2(OAc)2(dmf)2], is a triazolate complex, which contains two 3-(2-pyridyl)-5-ethyl-triazolates (L
Et)− in bidentate-bridged coordination modes. Both copper atoms are involved in the formation of a planar six-membered metallocycle Cu–[N—N]2–Cu. The inversion center of the complex is located at the mid-point of the Cu...Cu vector. Each CuII atom has a distorted trigonal–bipyramidal environment formed by the three nitrogen atoms of the deprotonated bridging 3-(2-pyridyl)-5-ethyl-triazolate unit, oxygen atoms of the OAc− group and dmf molecule. In the crystal, C—H...O hydrogen bonds link the molecules into chains running along the c-axis direction.
In the title compound [Fe2(C2O4)(C8H8N4)4](CH3C6H4SO3)2·2.75H2O, the two FeII ions have a highly distorted octahedral FeN4O2 environment formed by two bidentate triazole-based chelating ligands and a bis-bidentate oxalate bridging anion that connects the metal ions. Stabilization within the crystal structure is provided via a system of O—H...O and N—H...O hydrogen bonding, which determines the formation of a two-dimensional architecture along the a-axis direction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.